Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment

Irene Litvan*, Karl Kieburtz, Alexander I. Tröster, Dag Aarsland

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Citations (Scopus)

Abstract

Treatments to slow the progression of cognitive dysfunction to dementia and improve the quality of life of persons with Parkinson's disease (PD) are desperately needed. Because PD mild cognitive impairment is considered a transitional stage before dementia, it opens a window to timely intervention. This article critically reviews the strengths and challenges of pharmacologic and nonpharmacologic clinical therapeutic trials in PD mild cognitive impairment conducted during the past 5 years, including ongoing trials. Relatively few high-quality trials have been conducted, and some important factors in designing future clinical trials are discussed.

Original languageEnglish
Pages (from-to)520-527
Number of pages8
JournalMovement Disorders
Volume33
Issue number4
Early online date24 Mar 2018
DOIs
Publication statusPublished - Apr 2018

Keywords

  • clinical trials
  • mild cognitive impairment
  • nonpharmacologic
  • Parkinson disease
  • pharmacologic

Fingerprint

Dive into the research topics of 'Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment'. Together they form a unique fingerprint.

Cite this